← BIOVIE INC. (BIVI) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
BIOVIE INC. (BIVI)
Pharmaceutical Preparations · market cap $12M · as of 2026-07-21
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-09 (est.)
Earnings
Pipeline
2
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
BioVie Inc. (BIVI) is a micro-cap pharmaceutical company with an $11M market cap developing NE3107 in a Phase 3 trial for Parkinson's Disease as its lead asset, alongside terlipressin acetate continuous infusion in Phase 2 for cirrhosis. The company is in a precarious financial position with only $13.1M cash and an estimated 2.6-month runway, creating acute near-term financing risk ahead of its next catalyst expected around August 15, 2026.
The catalyst path
- 2026-11-09 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Terlipressin acetate continuous infusion | Phase 2 | Cirrhosis |
| NE3107 | Phase 3 | Parkinsons Disease (PD) |
Price & technical context
3-month
+21.0%
6-month
-21.4%
12-month
-20.9%
52-wk range
$0.96–$2.28
vs 50-day MA
-23.8%
vs 200-day MA
-20.5%
Realized vol
125.3%
Max drawdown
-97.3%
Daily closes through 2026-11-05. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for BIVI (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.